



Press Release

Company name: DAIICHI SANKYO COMPANY, LIMITED

Representative: Sunao Manabe, Representative Director, President and COO

(Code no.: 4568, First Section, Tokyo Stock Exchange)

Please address inquiries to Koji Ogawa, Corporate Officer,

Vice President, Corporate Communications Department

Telephone: +81-3-6225-1126

<https://www.daiichisankyo.com>

Daiichi Sankyo Announces Discontinuation of Intradermal Seasonal Influenza Vaccine Development in Japan

Tokyo, Japan, October 31, 2018 – Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) announced that it has decided to discontinue the development of an intradermal seasonal influenza vaccine (VN-100; hereafter, The Vaccine).

The Vaccine was designed by combining the intradermal administration device of Terumo Corporation (hereafter, Terumo) and the influenza HA vaccine of Kitasato Daiichi Sankyo Vaccine Co., Ltd. (hereafter, Kitasato Daiichi Sankyo), and was being jointly developed by Daiichi Sankyo, Terumo, Kitasato Daiichi Sankyo, and Japan Vaccine Co., Ltd., under an agreement concluded in February, 2012, between Daiichi Sankyo and Terumo on the practical application of intradermal vaccines for infectious diseases.

As a result of having reviewed the influenza vaccine project within the Daiichi Sankyo Group, Daiichi Sankyo has decided to discontinue the development of The Vaccine for strategic reasons. However, Daiichi Sankyo and Terumo will continue their partnership for the practical application of other intradermal vaccines besides The Vaccine.

Daiichi Sankyo will continue making efforts toward further improvement of public health in Japan, as well as contributing to the prevention and treatment of diseases in order to improve public health of Japanese people through the manufacture and supply of medicines, including vaccines.